1. Vemurafenib/RO518426 (Zelboraf™) Medical Review NDA 202429, FDA Oct 2011.
2. Zelboraf® (vemurafenib) Prescribing Information, Genentech, Roche Nov 2014.
3. Zelboraf® (vemurafenib) Assessment Report WC500124400, EMA Dec 2011.
4. Zelboraf ® (vemurafenib) EPAR WC500124317, Annex I, EMA Aug 2014.
5. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells;Halaban;Pigment Cell Melanoma Res,2010